Dabixta Capsule 75 mg contains Dabigatran Etexilate Mesylate 75 mg, an oral anticoagulant used to prevent and treat blood clots in various cardiovascular conditions. Dabigatran is a direct thrombin inhibitor that works by blocking the action of thrombin, a key enzyme responsible for converting fibrinogen into fibrin during the clotting process.

Blood clots can lead to serious complications such as stroke, myocardial infarction, or pulmonary embolism. Dabixta helps reduce the risk of these events by preventing abnormal clot formation in patients with atrial fibrillation, deep vein thrombosis (DVT), or pulmonary embolism (PE). Its targeted action ensures effective anticoagulation with a predictable effect, reducing the need for frequent laboratory monitoring associated with traditional anticoagulants like warfarin.

Dabixta Capsule 75 mg is particularly useful for patients requiring long-term anticoagulation therapy. It is absorbed orally, rapidly converted to its active form, and provides consistent anticoagulant effects, making it a convenient and effective option for thromboembolic risk management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Dabixta Capsule 75 mg is indicated for:

• Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

• Treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE)

• Prophylaxis of venous thromboembolism in patients undergoing orthopedic surgeries (as prescribed)

Key Benefits

• Reduces the risk of stroke and systemic embolism in atrial fibrillation

• Prevents formation and recurrence of dangerous blood clots

• Oral administration allows convenient, long-term therapy

• Predictable anticoagulant effect without frequent INR monitoring

• Rapid onset of action and consistent therapeutic effect

Mechanism of Action

Dabigatran Etexilate Mesylate is a prodrug that is converted to dabigatran in the body. Dabigatran directly inhibits thrombin (factor IIa), preventing the conversion of fibrinogen into fibrin, a key step in clot formation. By targeting thrombin, dabigatran reduces the development of blood clots while maintaining normal hemostasis, lowering the risk of both thromboembolic and bleeding complications.

Dosage and Administration

The dosage of Dabixta Capsule 75 mg should be individualized based on the patient’s condition, renal function, and risk of thromboembolism, as determined by a physician. Capsules should be swallowed whole with water, with or without food, at the same time each day.

Renal function should be monitored periodically, as dabigatran is primarily eliminated via the kidneys. Missed doses should be taken as soon as possible, but double dosing should be avoided.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use with caution in patients with kidney impairment or history of bleeding disorders

• Not recommended in patients with active pathological bleeding

• Inform your physician about any other medications, especially other anticoagulants or antiplatelet drugs

• Use cautiously in elderly patients and those with high bleeding risk

• Not recommended during pregnancy or breastfeeding unless clearly advised

Possible Side Effects

Dabixta Capsule 75 mg is generally well tolerated, though some patients may experience:

• Gastrointestinal symptoms such as nausea, indigestion, or abdominal pain

• Bleeding complications, including nosebleeds, gum bleeding, or bruising

• Rarely, severe hemorrhage requiring medical attention

Regular monitoring and reporting of unusual bleeding or bruising can help manage side effects effectively.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.